Name: Pregnenolone
Brand: Selleck Chemicals
SKU: S1914
Availability: InStock
Rating: 5 (5 reviews)

Jump to

Quality Control

Batch: Purity: 99.85%

99.85

Related Targets	Adrenergic Receptor GPR Androgen Receptor Glucocorticoid Receptor ACE RAAS Progesterone Receptor Opioid Receptor THR PGES
Other Estrogen/progestogen Receptor Inhibitors	Elacestrant (RAD1901) Dihydrochloride Vepdegestrant (ARV-471) MPP dihydrochloride Kaempferol Cholesterol PHTPP G15 Licochalcone A Endoxifen HCl Chrysin

Solubility

In vitro
Batch:

DMSO : 22 mg/mL (69.51 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 22 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.45mg/ml (1.42mM)	Taking the 1 mL working solution as an example, add 50 μL of 9 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% Corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	0.064mg/ml (0.20mM)	Taking the 1 mL working solution as an example, add 50 μL of 1.28 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	316.48	Formula	C₂₁H₃₂O₂	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	145-13-1	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	3β-Hydroxy-5-pregnen-20-one			SMILES	CC(=O)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

Targets/IC₅₀/Ki	progestogen Receptor
In vitro	Pregnenolone induces a large, dose-related increase of both the rate and extent of MAP2-induced tubulin assembly, whereas progesterone, inactive per se, counteracted the stimulatory effect of this compound. This compound-increased assembly of microtubules produces a completely normal structure. It preserves microtubule abundance and promotes cell movement during epiboly. This chemical results in dramatic reduction in GR nuclear localization in mouse hippocampal cell line (HT-22). It has neuroprotective effects against both glutamate and amyloid beta protein neuropathology.
In vivo	Pregnenolone sustains its proliferative activity in vivo and stimulates the growth of LNCaP-tumor xenografts in intact male SCID mice as well as in castrated animals. This compound is shown to activate transcription through the LNCaP androgen receptor (AR), but not the wild-type AR. It results in a significant decrease in the accumulation of astrocytes in the proximity of the wound and in a decreased bromodeoxyuridine incorporation in reactive astrocytes of rats. Administration of this chemical results in elevations in downstream neurosteroids such as allopregnanolone, a molecule with neuroprotective effects that also increases neurogenesis, decreases apoptosis and inflammation, modulates the hypothalamic-pituitary-adrenal axis, and markedly increases GABA(A) receptor responses. It elevates pregnenolone sulfate, a neurosteroid that positively modulates NMDA receptors.
References	[1] https://pubmed.ncbi.nlm.nih.gov/10737804/ [2] https://pubmed.ncbi.nlm.nih.gov/16437115/ [3] https://pubmed.ncbi.nlm.nih.gov/11358277/ [4] https://pubmed.ncbi.nlm.nih.gov/11179903/ [5] https://pubmed.ncbi.nlm.nih.gov/10221674/ [6] https://pubmed.ncbi.nlm.nih.gov/21756978/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-08-24)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07734701	NOT_YET_RECRUITING	Alcohol Use Disorder (AUD); Major Depressive Disorder (MDD)	Sherwood Brown, MD, PhD	2026-10	PHASE2
NCT05935761	NOT_YET_RECRUITING	Chronic Low Back Pain	VA Office of Research and Development	2026-09-01	PHASE2
NCT07685964	NOT_YET_RECRUITING	Cannabis Use Disorder; Major Depressive Disorder (MDD)	University of Texas Southwestern Medical Center	2026-09	PHASE1; PHASE2
NCT05781009	RECRUITING	Alcohol Use Disorder	Yale University	2024-01-08	PHASE2
NCT06188923	RECRUITING	Anxiety and Depression	VA Office of Research and Development	2025-08-14	PHASE2
NCT07216690	RECRUITING	Cannabis Intoxication	Johns Hopkins University	2026-04-24	PHASE2

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Pregnenolone Estrogen/progestogen Receptor modulator

Chemical Structure

Molecular Weight: 316.48